NCCN Categories of Evidence and Consensus
Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
All recommendations are category 2A unless otherwise noted.
Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Donohue JH, Stewart AK, Menck HR. The National Cancer Data Base report on carcinoma of the gallbladder, 1989-1995. Cancer 1998;83:2618–2628.
Levy AD, Murakata LA, Rohrmann CA Jr. Gallbladder carcinoma: radiologic-pathologic correlation. Radiographics 2001;21:295–314; questionnaire, 549-255.
Jarnagin WR, Ruo L, Little SA et al.. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003;98:1689–1700.
Sheth S, Bedford A, Chopra S. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol 2000;95:1402–1410.
Tazuma S, Kajiyama G. Carcinogenesis of malignant lesions of the gall bladder. The impact of chronic inflammation and gallstones. Langenbecks Arch Surg 2001;386:224–229.
Khan ZS, Livingston EH, Huerta S. Reassessing the need for prophylactic surgery in patients with porcelain gallbladder: case series and systematic review of the literature. Arch Surg 2011;146:1143–1147.
Elnemr A, Ohta T, Kayahara M et al.. Anomalous pancreaticobiliary ductal junction without bile duct dilatation in gallbladder cancer. Hepatogastroenterology 2001;48:382–386.
Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg 2007;11:671–681.
Fong Y, Wagman L, Gonen M et al.. Evidence-based gallbladder cancer staging: changing cancer staging by analysis of data from the National Cancer Database. Ann Surg 2006;243:767–771; discussion 771-764.
Duffy A, Capanu M, Abou-Alfa GK et al.. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol 2008;98:485–489.
Ito H, Ito K, D’Angelica M et al.. Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. Ann Surg 2011;254:320–325.
Hawkins WG, DeMatteo RP, Jarnagin WR et al.. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol 2004;11:310–315.
Furlan A, Ferris JV, Hosseinzadeh K, Borhani AA. Gallbladder carcinoma update: multimodality imaging evaluation, staging, and treatment options. AJR Am J Roentgenol 2008;191:1440–1447.
Petrowsky H, Wildbrett P, Husarik DB et al.. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006;45:43–50.
Corvera CU, Blumgart LH, Akhurst T et al.. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008;206:57–65.
Lee SW, Kim HJ, Park JH et al.. Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol 2010;45:560–566.
Strom BL, Maislin G, West SL et al.. Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer? Int J Cancer 1990;45:821–824.
Dixon E, Vollmer CM Jr, Sahajpal A et al.. An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg 2005;241:385–394.
Fuks D, Regimbeau JM, Le Treut YP et al.. Incidental gallbladder cancer by the AFC-GBC-2009 Study Group. World J Surg 2011;35:1887–1897.
Lee SE, Jang JY, Lim CS et al.. Systematic review on the surgical treatment for T1 gallbladder cancer. World J Gastroenterol 2011;17:174–180.
Foster JM, Hoshi H, Gibbs JF et al.. Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection. Ann Surg Oncol 2007;14:833–840.
Coburn NG, Cleary SP, Tan JC, Law CH. Surgery for gallbladder cancer: a population-based analysis. J Am Coll Surg 2008;207:371–382.
Jensen EH, Abraham A, Habermann EB et al.. A critical analysis of the surgical management of early-stage gallbladder cancer in the United States. J Gastrointest Surg 2009;13:722–727.
Downing SR, Cadogan KA, Ortega G et al.. Early-stage gallbladder cancer in the surveillance, epidemiology, and end results database: effect of extended surgical resection. Arch Surg 2011;146:734–738.
Shirai Y, Sakata J, Wakai T et al.. “Extended” radical cholecystectomy for gallbladder cancer: long-term outcomes, indications and limitations. World J Gastroenterol 2012;18:4736–4743.
D’Angelica M, Dalal KM, DeMatteo RP et al.. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol 2009;16:806–816.
Pawlik TM, Gleisner AL, Vigano L et al.. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg 2007;11:1478–1486; discussion 1486-1477.
Fong Y, Jarnagin W, Blumgart LH. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg 2000;232:557–569.
Shih SP, Schulick RD, Cameron JL et al.. Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg 2007;245:893–901.
Agarwal AK, Kalayarasan R, Javed A et al.. Role of staging laparoscopy in primary gall bladder cancer—an analysis of 409 patients: a prospective study to evaluate the role of staging laparoscopy in the management of gallbladder cancer. Ann Surg 2013;258:318–323.
Butte JM, Gonen M, Allen PJ et al.. The role of laparoscopic staging in patients with incidental gallbladder cancer. HPB (Oxford) 2011;13:463–472.
Maker AV, Butte JM, Oxenberg J et al.. Is port site resection necessary in the surgical management of gallbladder cancer? Ann Surg Oncol 2012;19:409–417.
Fuks D, Regimbeau JM, Pessaux P et al.. Is port-site resection necessary in the surgical management of gallbladder cancer? J Visc Surg 2013;150:277–284.
Regimbeau JM, Fuks D, Bachellier P et al.. Prognostic value of jaundice in patients with gallbladder cancer by the AFC-GBC-2009 study group. Eur J Surg Oncol 2011;37:505–512.
Wang SJ, Fuller CD, Kim JS et al.. Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol 2008;26:2112–2117.
Wang SJ, Lemieux A, Kalpathy-Cramer J et al.. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 2011;29:4627–4632.
Lim JH. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol 2003;181:819–827.
DeOliveira ML, Cunningham SC, Cameron JL et al.. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007;245:755–762.
Donato F, Gelatti U, Tagger A et al.. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001;12:959–964.
Yamamoto S, Kubo S, Hai S et al.. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004;95:592–595.
Shaib YH, El-Serag HB, Davila JA et al.. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005;128:620–626.
Welzel TM, Mellemkjaer L, Gloria G et al.. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer 2007;120:638–641.
Chang KY, Chang JY, Yen Y. Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw 2009;7:423–427.
Endo I, Gonen M, Yopp AC et al.. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008;248:84–96.
de Jong MC, Nathan H, Sotiropoulos GC et al.. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011;29:3140–3145.
Farges O, Fuks D, Le Treut YP et al.. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma. Cancer 2011;117:2170–2177.
de Jong MC, Hong SM, Augustine MM et al.. Hilar cholangiocarcinoma: tumor depth as a predictor of outcome. Arch Surg 2011;146:697–703.
Hong SM, Pawlik TM, Cho H et al.. Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. Surgery 2009;146:250–257.
Jarnagin WR, Fong Y, DeMatteo RP et al.. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507–517; discussion 517-509.
Matsuo K, Rocha FG, Ito K et al.. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg 2012;215:343–355.
Miller G, Schwartz LH, D’Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surg Oncol Clin N Am 2007;16:343–368.
Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009;15:4240–4262.
Sainani NI, Catalano OA, Holalkere NS et al.. Cholangiocarcinoma: current and novel imaging techniques. Radiographics 2008;28:1263–1287.
Halefoglu AM. Magnetic resonance cholangiopancreatography: a useful tool in the evaluation of pancreatic and biliary disorders. World J Gastroenterol 2007;13:2529–2534.
Hekimoglu K, Ustundag Y, Dusak A et al.. MRCP vs. ERCP in the evaluation of biliary pathologies: review of current literature. J Dig Dis 2008;9:162–169.
Vogl TJ, Schwarz WO, Heller M et al.. Staging of Klatskin tumours (hilar cholangiocarcinomas): comparison of MR cholangiography, MR imaging, and endoscopic retrograde cholangiography. Eur Radiol 2006;16:2317–2325.
Hyodo T, Kumano S, Kushihata F et al.. CT and MR cholangiography: advantages and pitfalls in perioperative evaluation of biliary tree. Br J Radiol 2012;85:887–896.
Kim JY, Kim MH, Lee TY et al.. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 2008;103:1145–1151.
Ruys AT, Bennink RJ, van Westreenen HL et al.. FDG-positron emission tomography/computed tomography and standardized uptake value in the primary diagnosis and staging of hilar cholangiocarcinoma. HPB (Oxford) 2011;13:256–262.
Nakagohri T, Asano T, Kinoshita H et al.. Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J Surg 2003;27:289–293.
Konstadoulakis MM, Roayaie S, Gomatos IP et al.. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery 2008;143:366–374.
Paik KY, Jung JC, Heo JS et al.. What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol 2008;23:766–770.
Lang H, Sotiropoulos GC, Sgourakis G et al.. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 2009;208:218–228.
Murakami Y, Uemura K, Sudo T et al.. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol 2011;18:651–658.
Ribero D, Pinna AD, Guglielmi A et al.. Surgical Approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. Arch Surg 2012;147:1107–1113.
Tamandl D, Herberger B, Gruenberger B et al.. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2008;15:2787–2794.
Farges O, Fuks D, Boleslawski E et al.. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg 2011;254:824–829; discussion 830.
Carpizo DR, D’Angelica M. Management and extent of resection for intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 2009;18:289–305, viii-ix.
Goere D, Wagholikar GD, Pessaux P et al.. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg Endosc 2006;20:721–725.
Shimada M, Yamashita Y, Aishima S et al.. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg 2001;88:1463–1466.
Choi SB, Kim KS, Choi JY et al.. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 2009;16:3048–3056.
Clark CJ, Wood-Wentz CM, Reid-Lombardo KM et al.. Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma: a population-based study using the National Cancer Institute SEER database. HPB (Oxford) 2011;13:612–620.
Morine Y, Shimada M, Utsunomiya T et al.. Clinical impact of lymph node dissection in surgery for peripheral-type intrahepatic cholangiocarcinoma. Surg Today 2012;42:147–151.
Fisher SB, Patel SH, Kooby DA et al.. Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis. HPB (Oxford) 2012;14:514–522.
Hyder O, Hatzaras I, Sotiropoulos GC et al.. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 2013;153:811–818.
Ribero D, Rosso S, Pinna AD et al.. Postoperative nomogram for predicting survival after resection for intrahepatic cholangiocarcinoma [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 4129.
Carrafiello G, Lagana D, Cotta E et al.. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. Cardiovasc Intervent Radiol 2010;33:835–839.
Kim JH, Won HJ, Shin YM et al.. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol 2011;196:W205–209.
Kiefer MV, Albert M, McNally M et al.. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 2011;117:1498–1505.
Kuhlmann JB, Euringer W, Spangenberg HC et al.. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol 2012;24:437–443.
- Search Google Scholar
- Export Citation
. Kuhlmann JB Euringer W Spangenberg HC Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol 2012; 24: 437– 443.
Hyder O, Marsh JW, Salem R et al.. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol 2013;20:3779–3786.
Poggi G, Quaretti P, Minoia C et al.. Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. Anticancer Res 2008;28:3835–3842.
Schiffman SC, Metzger T, Dubel G et al.. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann Surg Oncol 2011;18:431–438.
Ibrahim SM, Mulcahy MF, Lewandowski RJ et al.. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008;113:2119–2128.
Saxena A, Bester L, Chua TC et al.. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010;17:484–491.
Wijlemans JW, Van Erpecum KJ, Lam MG et al.. Trans-arterial (90)yttrium radioembolization for patients with unresectable tumors originating from the biliary tree. Ann Hepatol 2011;10:349–354.
Hoffmann RT, Paprottka PM, Schon A et al.. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012;35:105–116.
Rafi S, Piduru SM, El-Rayes B et al.. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol 2013;36:440–448.
Mouli S, Memon K, Baker T et al.. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol 2013;24:1227–1234.
Ortner ME, Caca K, Berr F et al.. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003;125:1355–1363.
Zoepf T, Jakobs R, Arnold JC et al.. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005;100:2426–2430.
Mambrini A, Guglielmi A, Pacetti P et al.. Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study. Anticancer Res 2007;27:3009–3013.
Shitara K, Ikami I, Munakata M et al.. Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma. Clin Oncol (R Coll Radiol) 2008;20:241–246.
Inaba Y, Arai Y, Yamaura H et al.. Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301). Am J Clin Oncol 2011;34:58–62.
Kemeny NE, Schwartz L, Gonen M et al.. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology 2011;80:153–159.
Akamatsu N, Sugawara Y, Hashimoto D. Surgical strategy for bile duct cancer: advances and current limitations. World J Clin Oncol 2011;2:94–107.
Qiao QL, Zhang TP, Guo JC et al.. Prognostic factors after pancreatoduodenectomy for distal bile duct cancer. Am Surg 2011;77:1445–1448.
Schwarz RE, Smith DD. Lymph node dissection impact on staging and survival of extrahepatic cholangiocarcinomas, based on U.S. population data. J Gastrointest Surg 2007;11:158–165.
Ito K, Ito H, Allen PJ et al.. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann Surg 2010;251:675–681.
Nishio H, Nagino M, Nimura Y. Surgical management of hilar cholangiocarcinoma: the Nagoya experience. HPB (Oxford) 2005;7:259–262.
Ito F, Agni R, Rettammel RJ et al.. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg 2008;248:273–279.
van Gulik TM, Kloek JJ, Ruys AT et al.. Multidisciplinary management of hilar cholangiocarcinoma (Klatskin tumor): extended resection is associated with improved survival. Eur J Surg Oncol 2011;37:65–71.
Cheng QB, Yi B, Wang JH et al.. Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type III and IV. Eur J Surg Oncol 2012;38:1197–1203.
Cho MS, Kim SH, Park SW et al.. Surgical outcomes and predicting factors of curative resection in patients with hilar cholangiocarcinoma: 10-year single-institution experience. J Gastrointest Surg 2012;16:1672–1679.
Lee SG, Song GW, Hwang S et al.. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Sci 2010;17:476–489.
de Jong MC, Marques H, Clary BM et al.. The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer 2012;118:4737–4747.
Wu XS, Dong P, Gu J et al.. Combined portal vein resection for hilar cholangiocarcinoma: a meta-analysis of comparative studies. J Gastrointest Surg 2013;17:1107–1115.
Connor S, Barron E, Wigmore SJ et al.. The utility of laparoscopic assessment in the preoperative staging of suspected hilar cholangiocarcinoma. J Gastrointest Surg 2005;9:476–480.
Weber SM, DeMatteo RP, Fong Y et al.. Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg 2002;235:392–399.
Kennedy TJ, Yopp A, Qin Y et al.. Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB (Oxford) 2009;11:445–451.
Liu F, Li Y, Wei Y, Li B. Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. Dig Dis Sci 2011;56:663–672.
Farges O, Regimbeau JM, Fuks D et al.. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 2013;100:274–283.
Abulkhir A, Limongelli P, Healey AJ et al.. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 2008;247:49–57.
Shindoh J, Vauthey JN, Zimmitti G et al.. Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach. J Am Coll Surg 2013;217:126–133.
- Search Google Scholar
- Export Citation
. Shindoh J Vauthey JN Zimmitti G Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach. J Am Coll Surg 2013; 217: 126– 133.
Davids PH, Groen AK, Rauws EA et al.. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992;340:1488–1492.
Prat F, Chapat O, Ducot B et al.. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc 1998;47:1–7.
Abraham NS, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc 2002;56:835–841.
Paik WH, Park YS, Hwang JH et al.. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc 2009;69:55–62.
Robles R, Figueras J, Turrion VS et al.. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg 2004;239:265–271.
Becker NS, Rodriguez JA, Barshes NR et al.. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 2008;12:117–122.
Kaiser GM, Sotiropoulos GC, Jauch KW et al.. Liver transplantation for hilar cholangiocarcinoma: a German survey. Transplant Proc 2008;40:3191–3193.
Friman S, Foss A, Isoniemi H et al.. Liver transplantation for cholangiocarcinoma: selection is essential for acceptable results. Scand J Gastroenterol 2011;46:370–375.
Darwish Murad S, Kim WR, Harnois DM et al.. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012;143:88–98.
Panjala C, Nguyen JH, Al-Hajjaj AN et al.. Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma. Liver Transpl 2012;18:594–601.
Duignan S, Maguire D, Ravichand CS et al.. Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience. HPB (Oxford) 2014;16:91–98.
Rea DJ, Heimbach JK, Rosen CB et al.. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005;242:451–458.
Hong JC, Jones CM, Duffy JP et al.. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 2011;146:683–689.
Cereda S, Belli C, Reni M. Adjuvant treatment in biliary tract cancer: to treat or not to treat? World J Gastroenterol 2012;18:2591–2596.
Glazer ES, Liu P, Abdalla EK et al.. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J Gastrointest Surg 2012;16:1666–1671.
Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012;30:1934–1940.
Takada T, Amano H, Yasuda H et al.. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685–1695.
Gold DG, Miller RC, Haddock MG et al.. Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys 2009;75:150–155.
Hughes MA, Frassica DA, Yeo CJ et al.. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007;68:178–182.
Nelson JW, Ghafoori AP, Willett CG et al.. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2009;73:148–153.
Lim KH, Oh DY, Chie EK et al.. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study. BMC Cancer 2009;9:345.
- Search Google Scholar
- Export Citation
. Lim KH Oh DY Chie EK Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study. BMC Cancer 2009; 9: 345.
Kim TH, Han SS, Park SJ et al.. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys 2011;81:e853–859.
Borghero Y, Crane CH, Szklaruk J et al.. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 2008;15:3147–3156.
- Search Google Scholar
- Export Citation
. Borghero Y Crane CH Szklaruk J Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol 2008; 15: 3147– 3156.
Park JH, Choi EK, Ahn SD et al.. Postoperative chemoradiotherapy for extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2011;79:696–704.
Das P, Wolff RA, Abbruzzese JL et al.. Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol 2006;1:41–41.
Lin LL, Picus J, Drebin JA et al.. A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma. Am J Clin Oncol 2005;28:234–241.
Park J, Kim MH, Kim KP et al.. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009;3:298–305.
Glimelius B, Hoffman K, Sjoden PO et al.. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593–600.
Sharma A, Dwary AD, Mohanti BK et al.. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010;28:4581–4586.
Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896–902.
Yonemoto N, Furuse J, Okusaka T et al.. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 2007;37:843–851.
Kornek GV, Schuell B, Laengle F et al.. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 2004;15:478–483.
Ducreux M, Van Cutsem E, Van Laethem JL et al.. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer 2005;41:398–403.
- Search Google Scholar
- Export Citation
. Ducreux M Van Cutsem E Van Laethem JL A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer 2005; 41: 398– 403.
Valle J, Wasan H, Palmer DH et al.. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273–1281.
Okusaka T, Nakachi K, Fukutomi A et al.. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010;103:469–474.
Doval DC, Sekhon JS, Gupta SK et al.. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004;90:1516–1520.
Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005;16:279–281.
Giuliani F, Gebbia V, Maiello E et al.. Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM). Ann Oncol 2006;17 Suppl 7:73–77.
Lee J, Kim TY, Lee MA et al.. Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol 2008;61:47–52.
Meyerhardt JA, Zhu AX, Stuart K et al.. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 2008;53:564–570.
Andre T, Reyes-Vidal JM, Fartoux L et al.. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008;99:862–867.
Harder J, Riecken B, Kummer O et al.. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006;95:848–852.
Kim HJ, Lee NS, Lee SC et al.. A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer. Cancer Chemother Pharmacol 2009;64:371–377.
Jang JS, Lim HY, Hwang IG et al.. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol 2010;65:641–647.
Alberts SR, Al-Khatib H, Mahoney MR et al.. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005;103:111–118.
Cho JY, Paik YH, Chang YS et al.. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 2005;104:2753–2758.
Knox JJ, Hedley D, Oza A et al.. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005;23:2332–2338.
Riechelmann RP, Townsley CA, Chin SN et al.. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 2007;110:1307–1312.
Koeberle D, Saletti P, Borner M et al.. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2008;26:3702–3708.
Iqbal S, Rankin C, Lenz HJ et al.. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol 2011;68:1595–1602.
Nehls O, Klump B, Arkenau HT et al.. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 2002;87:702–704.
Nehls O, Oettle H, Hartmann JT et al.. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008;98:309–315.
Kim TW, Chang HM, Kang HJ et al.. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003;14:1115–1120.
Kobayashi K, Tsuji A, Morita S et al.. A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma. BMC Cancer 2006;6:121–121.
Rao S, Cunningham D, Hawkins RE et al.. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005;92:1650–1654.
Yamashita Y, Taketomi A, Fukuzawa K et al.. Gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients with advanced biliary tree cancers: a pilot study. Anticancer Res 2006;26:771–775.
Wagner AD, Buechner-Steudel P, Moehler M et al.. Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. Br J Cancer 2009;101:1846–1852.
Sohal DP, Mykulowycz K, Uehara T et al.. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol 2013;24:3061–3065.
Ghafoori AP, Nelson JW, Willett CG et al.. Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2011;81:654–659.
Macdonald OK, Crane CH. Palliative and postoperative radiotherapy in biliary tract cancer. Surg Oncol Clin N Am 2002;11:941–954.
Czito BG, Anscher MS, Willett CG. Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) 2006;20:873–884.